21 May 2009
Predictors of kidney dysfunction in heart transplant recipients
P Przybyłowski, J Małyszko, J MałyszkoAnn Transplant 2009; 14(1): 32-32 :: ID: 880314
Abstract
Background: Cardiovascular disease and kidney disease seem to be lethally synergistic and both approach the level of epidemic. Patients with cardiovascular disease have often impaired kidney function, while on the other hand cardiovascular disease is the single best predictor of mortality in patients with chronic kidney disease. The risk in a patient with moderate impaired renal function is comparable in magnitude with that of a patient with diabetes mellitus. The aim of the study was to assess the risk factors for kidney dysfunction in a 162 consecutive heart transplant recipients (129 males, 22 females). Stages of chronic kidney disease were defi ned according to K/DOQI guidelines using estimated GFR.
Results: Mean serum creatinine in this population was 1.70±1.08 mg/dl (ranges from 0.54-9.34 mg/dl); mean age was 54±14 years; mean time after transplantation was 106±52 months (ranges 10-210 months). Mean GFR was 62.92±31.04 ml/min (Cockcroft-Gault formula), 55.38±26.74 ml/min (MDRD) and 62.62±35.61 ml/min (creatinine clearance). Estimated GFR, creatinine clearance, serum creatinine correlated in univariate analysis with haemoglobin, RBC count, age, time after transplantation, ejection fraction, NT-proBNP, use of calcineurine inhibitors. In multiple regression analysis predictors of kidney function (GFR) were age (beta value -0.47, p<0.001), time after transplantation (beta value -0.22, p=0.03) and haemoglobin (beta value 0.31, p-0.03) explaining the 51% of variation of GFR in this group. When GFR was substituted by creatinine clearance the results were the same. Conclusions: In heart transplant recipients kidney function is predominantly dependent upon age, time after transplantation (both non-modifi able causes) and anaemia (which could be modified).
Keywords: Heart Transplantation, Immunosuppression
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






